La Jolla Pharmaceutical Past Earnings Performance
Past criteria checks 3/6
La Jolla Pharmaceutical has been growing earnings at an average annual rate of 40.6%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 53.7% per year.
Key information
40.6%
Earnings growth rate
44.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 53.7% |
| Return on equity | n/a |
| Net Margin | 8.5% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How La Jolla Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 46 | 4 | 38 | 3 |
| 31 Mar 22 | 52 | 5 | 37 | 3 |
| 31 Dec 21 | 76 | 20 | 35 | 5 |
| 30 Sep 21 | 74 | 12 | 36 | 6 |
| 30 Jun 21 | 70 | 3 | 37 | 7 |
| 31 Mar 21 | 60 | -16 | 35 | 11 |
| 31 Dec 20 | 33 | -39 | 36 | 18 |
| 30 Sep 20 | 30 | -61 | 39 | 30 |
| 30 Jun 20 | 26 | -79 | 44 | 48 |
| 31 Mar 20 | 26 | -93 | 47 | 61 |
| 31 Dec 19 | 23 | -117 | 52 | 73 |
| 30 Sep 19 | 20 | -137 | 64 | 77 |
| 30 Jun 19 | 18 | -158 | 70 | 145 |
| 31 Mar 19 | 14 | -181 | 81 | 128 |
| 31 Dec 18 | 10 | -199 | 90 | 108 |
| 30 Sep 18 | 6 | -193 | 78 | 90 |
| 30 Jun 18 | 2 | -168 | 65 | 0 |
| 31 Mar 18 | 1 | -142 | 48 | 0 |
| 31 Dec 17 | 0 | -115 | 31 | 0 |
| 30 Sep 17 | 0 | -101 | 24 | 0 |
| 30 Jun 17 | 0 | -96 | 21 | 0 |
| 31 Mar 17 | 0 | -85 | 18 | 0 |
| 31 Dec 16 | 1 | -78 | 17 | 0 |
| 30 Sep 16 | 1 | -65 | 15 | 0 |
| 30 Jun 16 | 2 | -54 | 14 | 0 |
| 31 Mar 16 | 1 | -49 | 14 | 0 |
| 31 Dec 15 | 1 | -42 | 14 | 0 |
| 30 Sep 15 | 1 | -37 | 14 | 0 |
Quality Earnings: LJPP has a large one-off gain of $2.3M impacting its last 12 months of financial results to 30th June, 2022.
Growing Profit Margin: LJPP's current net profit margins (8.5%) are higher than last year (4.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LJPP has become profitable over the past 5 years, growing earnings by 40.6% per year.
Accelerating Growth: LJPP's earnings growth over the past year (36.3%) is below its 5-year average (40.6% per year).
Earnings vs Industry: LJPP earnings growth over the past year (36.3%) exceeded the Biotechs industry -26.8%.
Return on Equity
High ROE: LJPP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.